NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 198 filers reported holding NOVOCURE LTD in Q2 2019. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $531,000 | +141.4% | 4,569 | +174.9% | 0.02% | +120.0% |
| Q1 2021 | $220,000 | -88.6% | 1,662 | -94.2% | 0.01% | -81.5% |
| Q1 2020 | $1,934,000 | -73.4% | 28,727 | -66.7% | 0.05% | -59.4% |
| Q4 2019 | $7,270,000 | +7.1% | 86,272 | -5.0% | 0.13% | +10.8% |
| Q3 2019 | $6,791,000 | +90.4% | 90,811 | +61.0% | 0.12% | +110.5% |
| Q2 2019 | $3,567,000 | +933.9% | 56,409 | +688.4% | 0.06% | +1040.0% |
| Q1 2019 | $345,000 | -48.8% | 7,155 | -76.9% | 0.01% | -44.4% |
| Q1 2018 | $674,000 | -0.3% | 30,924 | -7.5% | 0.01% | -10.0% |
| Q4 2017 | $676,000 | -7.5% | 33,445 | -9.1% | 0.01% | -9.1% |
| Q3 2017 | $731,000 | +36.9% | 36,802 | +19.2% | 0.01% | +57.1% |
| Q2 2017 | $534,000 | – | 30,878 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |